Clinical trials: Major Adverse Cardiovascular Events (MACE)
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Chronic Total Occlusion of Coronary Artery
A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter
This is a prospective, non-randomized, first-in-man investigational study, to assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional…
- Trial name
- NCT01978860
- Testing
- NovaCross, CTO
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Chanan Schneider
Hypotension, Postoperative Complications
Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery
Major adverse cardiovascular events (MACE) are a leading cause of serious complications and death following major noncardiac surgery.
- Conditions
- Hypotension, Postoperative Complications, Acute Coronary Syndrome, Heart Failure
- Trial name
- BBB (NCT02533128)
- Testing
- Liberal blood pressure management, Tight blood pressure management
- Where
- Switzerland
- Volunteers
- 458 people
- Sponsor
- Miodrag Filipovic, Prof. Dr. med.
Obesity
Effects of OAGB and DJB-SG on 10-year and Lifetime Risks of MACE
Metabolic bariatric surgery (MBS) has demonstrated its efficacy in achieving sustainable weight loss and alleviating associated comorbidities.
- Trial name
- NCT06254339
- Testing
- OAGB, DJB-SG
- Volunteers
- 830 people
- Sponsor
- National Defense Medical Center, Taiwan
Peripheral Arterial Disease, Myocardial Injury
Cardiovascular Risk in Peripheral Artery Disease Patients Undergoing Endovascular Revascularisation
This study will investigate heart-related complications in patients with peripheral arterial disease (PAD) undergoing endovascular revascularization procedures to improve blood flow in the legs.
- Conditions
- Peripheral Arterial Disease, Myocardial Injury, Troponin, NT-proBNP
- Trial name
- RISK (NCT07599540)
- Where
- Slovenia
- Volunteers
- 500 people
- Sponsor
- University Medical Centre Ljubljana
Coronary Artery Disease, Coronary Artery Bypass Grafting
CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial
The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography, Coronary Angiography (CAG)
- Trial name
- CtaCAB (NCT07769008)
- Testing
- CCTA-based CABG, CAG-based CABG
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Ruijin Hospital
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Coronary Artery Disease
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease.
- Trial name
- NCT00868855
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Hypogonadism, Cardiovascular Diseases
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
- Trial name
- TRAVERSE (NCT03518034)
- Testing
- AndroGel®
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 5,246 people
- Sponsor
- AbbVie
Acquired Long QT, Ventricular Arrhythmias
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence.
- Conditions
- Acquired Long QT, Ventricular Arrhythmias, Torsades de Pointes, Syncope
- Trial name
- QTP-MACE (NCT07374263)
- Where
- 2 sites in Canada
- Volunteers
- 990,000 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Left Ventricular Remodeling, Plasma Multi-Omics
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to…
- Conditions
- Left Ventricular Remodeling, Plasma Multi-Omics, Acute ST-segment Elevation Myocardial Infarction, Immunomics
- Trial name
- NCT06885619
- Testing
- Diagnostic Test: echocardiography and blood collection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Cardiomyopathy, Arrhythmia-induced Cardiomyopathy (AiCM)
Characterization of Arrhythmia-induced Cardiomyopathy
The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.
- Trial name
- NCT05662293
- Testing
- Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part), Data collection: Quality of Life (QoL) Questionnaire (prospective part), Data collection (retrospective study)
- Where
- Switzerland
- Volunteers
- 2,700 people
- Sponsor
- University Hospital, Basel, Switzerland
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China RCT Study
It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03466151
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Medtronic Vascular
MACE, Cardiac Death
Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform
The goal of this observational study is to observe the characteristics of cardiopulmonary exercise testing (CPET) parameters in patients across different cardiovascular diseases and to evaluate the predictive value of…
- Conditions
- MACE, Cardiac Death, Unplanned Repeat Revascularization, Cardiac Rehospitalization
- Trial name
- China-CPET (NCT07130968)
- Where
- China
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Hip Fracture, MACE
AI-Based Risk Factor Analysis and Prediction Model of MACE in Elderly Hip Fracture Patients Postoperatively
This is a multicenter ambispective observational cohort study led by Beijing Anzhen Hospital, Capital Medical University, with China-Japan Friendship Hospital serving as the external validation center.
- Conditions
- Hip Fracture, MACE, Elderly, Perioperative Complications
- Trial name
- NCT07709377
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Anzhen Hospital
Living Donor Nephrectomy, Living Kidney Donation
Long-term Risk of Cardiovascular Disease in Living Kidney Donors
The investigative team will conduct a population-based, matched retrospective cohort study across Ontario, Alberta, and British Columbia using linked administrative healthcare databases to evaluate the long-term risk of major…
- Conditions
- Living Donor Nephrectomy, Living Kidney Donation, Living Kidney Donor, Living Kidney Donors
- Trial name
- NCT07431515
- Testing
- Nephrectomy
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Statin Dose
Effective Dose of Statin Post PCI
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
- Trial name
- NCT04923152
- Testing
- moderate statin dose, high dose statin
- Where
- Iran
- Volunteers
- 582 people
- Sponsor
- Shiraz University of Medical Sciences
Cardiovascular Surgical Procedures, Major Adverse Cardiovascular Events (MACE)
Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery
This study is a multicenter, randomized controlled, double-blind, placebo-controlled parallel trial designed to evaluate the effect of perioperative supplementation with Compound Vitamin B on patients undergoing cardiovascular…
- Trial name
- PANDA XII (NCT07348328)
- Testing
- Compound Vitamin B tablet, Control
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Nanjing Medical University